MarketBeat
11 Nov 2026, 02:16 UTC · 14h ago
Freenome Q3 Earnings Call Highlights
Impact · against what's priced in
Freenome's results reveal that its massive Q3 revenue was a non-recurring milestone payment, not a commercial run-rate, while its cash position provides a clear runway to 2028. For Abbott, the deployment of 800 reps and the $920 Medicare price point provide tactical progress, but do not yet shift the needle on the high revenue growth hurdles the market currently declines to pay for.
- ABT+0.10
Already priced in
- The price assumes
A 7% organic growth target
The deployment of 800 sales reps and the establishment of a $920 Medicare price for SimpleScreen CRC support the company's organic growth efforts, but these incremental steps do not yet challenge the market's refusal to price in sustained double-digit growth.
What ABT's price assumes · Sep 12
